Welcome to our dedicated page for Cidara Theraptcs SEC filings (Ticker: CDTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cidara Therapeutics, Inc. (CDTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a former Nasdaq-listed biotechnology issuer. These documents include current reports on Form 8-K, financing-related filings, and other materials that describe Cidara’s clinical development plans, capital structure changes, government agreements, and its acquisition by Merck.
For investors and researchers analyzing Cidara’s business, the company’s 8-K filings are especially important. They detail key events such as the Agreement and Plan of Merger with Merck Sharp & Dohme LLC and a Merck subsidiary, the terms of the cash tender offer for all outstanding shares of common and Series A preferred stock, and the planned merger that will make Cidara a wholly owned subsidiary of Merck. These filings also outline conditions to closing, tender offer mechanics, termination fees, and other transaction terms.
Other 8-K reports describe Cidara’s clinical and regulatory progress with CD388. For example, filings explain updates to the planned Phase 3 registrational trial following an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), including expansion of the ANCHOR study population and the intention to seek biologics license application (BLA) approval based on a single Phase 3 study. Additional filings summarize positive topline results from the Phase 2b NAVIGATE trial and provide context on safety and prevention efficacy data.
Cidara’s filings also cover its Award/Contract with the Biomedical Advanced Research and Development Authority (BARDA) to support expanded manufacturing and clinical development of CD388, including base-period funding for onshoring manufacturing to the United States and potential option funding for further studies. Capital markets transactions, such as underwritten public offerings of common stock and suspension of an at-the-market (ATM) prospectus, are documented in 8-Ks that describe underwriting agreements, share issuance, and related legal opinions.
On Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that highlight the main points of each document. Users can quickly see what each 8-K, registration-related filing, or other report means for Cidara’s clinical programs, financing, and merger process. While Cidara’s common stock is expected to cease trading on the Nasdaq Global Market following completion of its merger with Merck, its historical filings remain a key resource for understanding the evolution of CD388, the Cloudbreak platform, and the corporate steps leading to the acquisition.
RA Capital Management, its principals Peter Kolchinsky and Rajeev Shah, and RA Capital Healthcare Fund report beneficial ownership of 3,365,523 shares of Cidara Therapeutics common stock, representing 13.3% of 25,358,051 shares outstanding. The Fund also holds Series A preferred stock convertible into up to 6,296,920 common shares and pre-funded warrants exercisable for up to 1,286,786 common shares, but conversion and exercise are limited by contractual Beneficial Ownership Blockers that prevent the Fund from owning more than 9.99% of the common stock and currently prohibit conversion or exercise.
RA Capital is the investment adviser with sole power to vote and dispose of the Fund’s reported securities, and the Fund has delegated those powers and disclaims beneficial ownership for Section 13(d) purposes. No transactions have been reported since the prior amendment; the reported percentage reflects an increase in the issuer’s outstanding shares.
Cidara Therapeutics, Inc. (Nasdaq: CDTX) filed an 8-K describing a capital-raising transaction. On 24 June 2025 the company entered into an underwriting agreement with J.P. Morgan, Morgan Stanley, Guggenheim Securities and Cantor Fitzgerald for an underwritten public offering of common stock.
- Base offering: 7,954,546 shares of common stock.
- Public price: $44.00 per share.
- Gross proceeds: ≈ $350 million before fees and expenses.
- Over-allotment option: Underwriters may buy up to 1,193,181 additional shares (30-day option).
- Use of shelf: Shares are being issued under effective Form S-3 (File No. 333-287104).
- Closing date: Expected on or about 26 June 2025, subject to customary conditions.
The underwriting agreement contains standard representations, warranties, indemnities and termination rights. Copies of the agreement (Ex. 1.1), legal opinion (Ex. 5.1/23.1) and the press releases announcing the launch and pricing (Ex. 99.1, 99.2) are incorporated by reference.
Investor considerations: The transaction will strengthen Cidara’s cash position by up to $350 million (excluding any proceeds from the option) but will dilute existing shareholders through the issuance of roughly 8.0 million new shares (up to 9.1 million if the option is fully exercised). The offering has not yet closed; market conditions or failure to satisfy closing conditions could stop the deal.
Cidara Therapeutics, Inc. (Nasdaq: CDTX) has filed a Rule 424(b)(5) prospectus supplement to offer 7,954,546 newly-issued shares of common stock at $44.00 per share. Gross proceeds are expected to total $350.0 million; after underwriting discounts of $2.64 per share (total $21.0 million) the company anticipates pre-expense net proceeds of $329.0 million.
The underwriting syndicate is led by J.P. Morgan and Morgan Stanley, with Guggenheim Securities and Cantor also acting as joint book-runners. Cidara has granted the underwriters a 30-day option to purchase up to 1,193,181 additional shares at the public price less underwriting discounts. If fully exercised, total gross proceeds would rise to approximately $404.2 million, net proceeds (before expenses) to $378.35 million, and total underwriting fees to $24.15 million.
Use of capital & strategic context
Cidara is a clinical-stage biotechnology company developing drug-Fc conjugate (DFC) antivirals via its proprietary Cloudbreak® platform. Following the April 2024 divestiture of rezafungin, the company’s sole R&D focus is CD388, a long-acting, broad-spectrum neuraminidase inhibitor intended to provide single-dose seasonal and pandemic influenza prophylaxis. The company reacquired worldwide rights to CD388 from Janssen in April 2024 and paid an $85 million upfront fee funded by a $240 million private placement. An additional $105 million private placement was completed in November 2024.
Recent clinical milestone
On June 23, 2025, Cidara announced positive topline data from its 5,041-subject, randomized, double-blind, placebo-controlled Phase 2b NAVIGATE study in healthy adults aged 18-64. A single pre-season dose of CD388 achieved statistically significant prevention efficacy (PE) across all dose cohorts:
- 150 mg: PE = 57.7% (95% CI 21.1-78.9; p = 0.0050)
- 300 mg: PE = 61.3% (95% CI 27.0-81.2; p = 0.0024)
- 450 mg: PE = 76.1% (95% CI 49.3-89.9; p < 0.001)
Key considerations for investors
- The offering will provide substantial capital to advance CD388 into late-stage development and potential commercialization.
- Share issuance will dilute existing shareholders; exact dilution is detailed in the "Dilution" section (S-13) of the prospectus supplement.
- Cidara qualifies as a "smaller reporting company," allowing reduced disclosure requirements.
- Investment risk remains elevated: the company is now effectively a single-asset influenza play and clinical success is not yet validated in Phase 3 or by regulators.
Cidara Therapeutics (NASDAQ: CDTX) announced the suspension and termination of its ATM (At-The-Market) Prospectus dated May 15, 2025, which was established under the Open Market Sale Agreement with Jefferies LLC on May 8, 2025.
Key details of the announcement:
- The company will cease all common stock sales under the current Sales Agreement until a new prospectus or prospectus supplement is filed with the SEC
- The underlying Sales Agreement with Jefferies remains in full force and effect
- The original Sales Agreement was disclosed in the company's Quarterly Report filed on May 8, 2025
This strategic move suggests potential changes in Cidara's capital raising strategy or market conditions. The termination of the ATM Prospectus could indicate the company is considering alternative financing options or adjusting its capital structure.